Free shipping on all orders over $ 500

Icenticaftor

Cat. No. M21140
Icenticaftor Structure
Synonym:

QBW251

Size Price Availability Quantity
1mg USD 450  USD450 In stock
5mg USD 900  USD900 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Icenticaftor (QBW251) is an oral enhancer of the cystic fibrosis transmembrane conductance regulator (CFTR) channel with an EC50 of 79 nM for F508del and 497 nM for G551D CFTR. Icenticaftor can be used in chronic obstructive pulmonary disease (COPD) and cystic fibrosis studies.

Chemical Information
Molecular Weight 361.24
Formula C12H13F6N3O3
CAS Number 1334546-77-8
Solubility (25°C) DMSO ≥ 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Laura Carrasco-Hernndez, et al. Biomedicines. Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine

[2] Darren Le Grand, et al. J Med Chem. Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

[3] Shamsah Kazani, et al. J Cyst Fibros. Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)

[4] Steven M Rowe, et al. Int J Chron Obstruct Pulmon Dis. Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial

Related CFTR Products
GLPG2737

GLPG2737 is a novel potent Type 2 corrector of CFTR. GLPG2737 showed high permeability both in MDCKII-MDRI and Caco-2 cells, with low efflux allowing an elevated absorbed fraction FaxFg and a dose proportional increase in exposure in rat from a dose of 5 to 300 mg/kg, despite a low aqueous thermodynamic solubility.

UCCF-853

UCCF-853 is a cystic fibrosis transmembrane regulatory protein (CFTR) modulator.

(R)-Posenacaftor sodium

(R)-Posenacaftor sodium is the R-enantiomer of Posenacaftor and a cystic fibrosis transmembrane regulatory protein (CFTR) modulator that corrects the folding and transport of CFTR proteins.Posenacaftor is used in studies related to cystic fibrosis (CF).

(R)-Olacaftor

(R)-Olacaftor is a cystic fibrosis transmembrane regulator (CFTR) modulator that can be used in cystic fibrosis (CF) related studies.

CFTR corrector 9

CFTR corrector 9 is a cystic fibrosis transmembrane conductance regulator protein (CFTR) modulator for cystic fibrosis (CF) and other CFTR-related diseases.

  Catalog
Abmole Inhibitor Catalog




Keywords: Icenticaftor, QBW251 supplier, CFTR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.